Given the efficacy and need for effective therapies such as amikacin liposome inhalation suspension for MAC lung disease, what clinical strategies do you recommend for optimizing adherence, patient satisfaction, and tolerability for this formulation?

Given the efficacy and need for effective therapies such as amikacin liposome inhalation suspension for MAC lung disease, what clinical strategies do you recommend for optimizing adherence, patient satisfaction, and tolerability for this formulation?

CLICK HERE FOR CME CREDIT

Given the efficacy and need for effective therapies such as amikacin liposome inhalation suspension for MAC lung disease, what clinical strategies do you recommend for optimizing adherence, patient satisfaction, and tolerability for this formulation?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina